Atara Biotherapeutics Stock Performance
| ATRA Stock | USD 11.47 0.86 8.11% |
Atara Biotherapeutics holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.43, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Atara Biotherapeutics will likely underperform. Use Atara Biotherapeutics sortino ratio, semi variance, and the relationship between the information ratio and value at risk , to analyze future returns on Atara Biotherapeutics.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Atara Biotherapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Atara Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.81 | Five Day Return (13.87) | Year To Date Return (7.33) | Ten Year Return (98.36) | All Time Return (95.82) |
Last Split Factor 1:25 | Last Split Date 2024-06-20 |
1 | Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | 09/04/2024 |
2 | Acquisition by Anhco Nguyen of 45000 shares of Atara Biotherapeutics subject to Rule 16b-3 | 09/09/2024 |
3 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 10/04/2024 |
4 | Disposition of 68991 shares by Joshi Manher of Atara Biotherapeutics at 10.21 subject to Rule 16b-3 | 10/10/2024 |
5 | Atara Biotherapeutics Upgraded to Buy Heres What You Should Know | 10/15/2024 |
6 | Global Biopharma Thought Leaders Gather in London Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights | 10/24/2024 |
7 | Beam Therapeutics Inc. Reports Q3 Loss, Misses Revenue Estimates | 11/05/2024 |
8 | Atara Biotherapeutics, Inc. Surges 34 percent Yet Its Low PS Is No Reason For Excitement | 11/06/2024 |
9 | Atara Biotherapeutics GAAP EPS of -2.93 beats by 17.16, revenue of 40.19M beats by 5.02M | 11/12/2024 |
10 | Stifel raises Atara Bio shares target, keeps hold rating ahead of clinical data | 11/13/2024 |
11 | Atara Biotherapeutics Posts Quarterly Earnings Results, Beats Estimates By 0.84 EPS | 11/15/2024 |
12 | Atara biotherapeutics CFO Eric Hyllengren sells 15,274 in stock | 11/20/2024 |
| Begin Period Cash Flow | 93.1 M |
Atara |
Atara Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 703.00 in Atara Biotherapeutics on August 24, 2024 and sell it today you would earn a total of 444.00 from holding Atara Biotherapeutics or generate 63.16% return on investment over 90 days. Atara Biotherapeutics is currently generating 1.0584% in daily expected returns and assumes 7.985% risk (volatility on return distribution) over the 90 days horizon. In different words, 71% of stocks are less volatile than Atara, and 79% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atara Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atara Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atara Biotherapeutics, and traders can use it to determine the average amount a Atara Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1325
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ATRA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.99 actual daily | 71 71% of assets are less volatile |
Expected Return
| 1.06 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Atara Biotherapeutics is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atara Biotherapeutics by adding it to a well-diversified portfolio.
Atara Biotherapeutics Fundamentals Growth
Atara Stock prices reflect investors' perceptions of the future prospects and financial health of Atara Biotherapeutics, and Atara Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atara Stock performance.
| Return On Equity | -20.15 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 43.82 M | ||||
| Shares Outstanding | 5.76 M | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.98 X | ||||
| Revenue | 8.57 M | ||||
| Gross Profit | 63.57 M | ||||
| EBITDA | (266 M) | ||||
| Net Income | (276.13 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 57.87 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (23.30) X | ||||
| Cash Flow From Operations | (192.98 M) | ||||
| Earnings Per Share | (25.32) X | ||||
| Market Capitalization | 61.11 M | ||||
| Total Asset | 165.5 M | ||||
| Retained Earnings | (1.97 B) | ||||
| Working Capital | (40.36 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
About Atara Biotherapeutics Performance
By analyzing Atara Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Atara Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Atara Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Atara Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 398.68 | 418.62 | |
| Return On Tangible Assets | (1.67) | (1.75) | |
| Return On Capital Employed | (11.86) | (11.26) | |
| Return On Assets | (1.67) | (1.75) | |
| Return On Equity | 2.78 | 2.92 |
Things to note about Atara Biotherapeutics performance evaluation
Checking the ongoing alerts about Atara Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atara Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atara Biotherapeutics is way too risky over 90 days horizon | |
| Atara Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Atara Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.57 M. Net Loss for the year was (276.13 M) with profit before overhead, payroll, taxes, and interest of 63.57 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Atara biotherapeutics CFO Eric Hyllengren sells 15,274 in stock |
- Analyzing Atara Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atara Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Atara Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atara Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atara Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atara Biotherapeutics' stock. These opinions can provide insight into Atara Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |